<p>加利福尼亚州南旧金山，2025 年 12 月 18 日（GLOBE NEWSWIRE）-- Senti Biosciences, Inc.（纳斯达克代码：SNTI）（“Senti Bio”）是一家临床阶段的生物技术公司，利用其专有的基因电路平台开发下一代细胞和基因疗法。今天宣布，自 2025 年 12 月 12 日起，Senti Bio 的董事会向一名新员工授予了购买公司普通股总计 13,680 股的股票期权，每股行使价格为 1.31 美元。这些奖励是根据公司的修订和重述的 2022 年诱导股权计划（“计划”）授予的。</p>
<p>上述奖励是作为员工与公司签订雇佣合同的诱因，根据纳斯达克上市规则 5635(c)(4) 授予，并根据计划的条款授予。该计划最初于 2022 年 8 月 5 日由公司的董事会通过。</p>
<p><strong>关于 Senti Bio</strong></p>
<p>Senti Bio 是一家生物技术公司，致力于为患有不治之症的患者开发新一代细胞和基因疗法。为此，Senti Bio 利用其合成生物学平台，将基因电路工程化为具有更高精度和控制力的新药物。这些基因电路旨在精确杀死癌细胞，保护健康细胞，提高对靶组织的特异性，并且/或者在给药后仍可控制。公司的全资管线包括针对难治性液体和实体肿瘤指征的基因电路工程化细胞疗法。Senti 的基因电路在临床前研究中已显示出在 NK 细胞和 T 细胞中的有效性。Senti Bio 还在临床前研究中展示了基因电路在肿瘤学以外的其他治疗方式和疾病中的潜在广泛应用，并通过合作不断推进这些能力。</p>
<p><strong>关于 Senti Bio 的其他信息的获取</strong></p>
<p>欲了解更多信息，请访问 Senti Bio 网站 https://www.sentibio.com 或在 X（前身为 Twitter）上关注 Senti Bio（@SentiBio）和 LinkedIn（Senti Biosciences）。投资者和其他人应注意，我们通过公司网站（www.sentibio.com）与投资者和公众沟通，包括但不限于公司披露、投资者演示和常见问题解答、证券交易委员会的文件、新闻稿、公开电话会议记录和网络广播记录，以及在 X 和 LinkedIn 上的信息。我们在网站或 X 或 LinkedIn 上发布的信息可能被视为重要信息。因此，我们鼓励投资者、媒体和其他感兴趣的人定期查看我们发布的信息。我们网站或社交媒体的内容不应被视为在 1933 年证券法修订案下的任何文件中引用。</p>
<p><strong>投资者联系：</strong></p>
<p>JTC Team, LLC</p>
<p>Jenene Thomas</p>
<p>(908) 824-0775</p>
<p>SNTI@jtcir.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd05EZ3hNU00zTXpJNU5qUTVJekl5TURrNE9EYz0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd05EZ3hNU00zTXpJNU5qUTVJekl5TURrNE9EYz0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MmVlYWFjOGMtNjhkYS00OWQwLTg0NjYtOGEyMjI2ODJkYmVmLTEyMjE0NDAtMjAyNS0xMi0xOC1lbg==/tiny/Senti-Biosciences-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MmVlYWFjOGMtNjhkYS00OWQwLTg0NjYtOGEyMjI2ODJkYmVmLTEyMjE0NDAtMjAyNS0xMi0xOC1lbg==/tiny/Senti-Biosciences-Inc-.png"/></p>

SNTI

<p>Senti Biosciences 宣布将于 2025 年 12 月 12 日生效的新员工诱因奖励。董事会根据修订和重述的 2022 年诱因股权计划授予一名新员工 13,680 股股票期权，行权价为每股 1.31 美元。这些奖励是作为就业诱因材料发放的，符合纳斯达克上市规则 5635(c)(4)。Senti Bio 是一家生物技术公司，利用其基因电路平台开发细胞和基因疗法</p>

<p>SOUTH SAN FRANCISCO, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that effective December 12, 2025 Senti Bio’s Board of Directors granted to one new employee stock options to purchase an aggregate of 13,680 shares of the Company’s common stock with a per share exercise price of $1.31 per share. These awards were made under the Company’s Amended and Restated 2022 Inducement Equity Plan (the “Plan”).</p>
<div class="lb-trans"><p>加利福尼亚州南旧金山，2025 年 12 月 18 日（GLOBE NEWSWIRE）-- Senti Biosciences, Inc.（纳斯达克代码：SNTI）（“Senti Bio”）是一家临床阶段的生物技术公司，利用其专有的基因电路平台开发下一代细胞和基因疗法。今天宣布，自 2025 年 12 月 12 日起，Senti Bio 的董事会向一名新员工授予了购买公司普通股总计 13,680 股的股票期权，每股行使价格为 1.31 美元。这些奖励是根据公司的修订和重述的 2022 年诱导股权计划（“计划”）授予的。</p>
</div><p>The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4), and were granted pursuant to the terms of the Plan. The Plan was initially adopted by the Company’s board of directors on August 5, 2022.</p>
<div class="lb-trans"><p>上述奖励是作为员工与公司签订雇佣合同的诱因，根据纳斯达克上市规则 5635(c)(4) 授予，并根据计划的条款授予。该计划最初于 2022 年 8 月 5 日由公司的董事会通过。</p>
</div><p><strong>About Senti Bio</strong></p>
<div class="lb-trans"><p><strong>关于 Senti Bio</strong></p>
</div><p>Senti Bio is a biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases. To achieve this, Senti Bio is leveraging its synthetic biology platform to engineer Gene Circuits into new medicines with enhanced precision and control. These Gene Circuits are designed to precisely kill cancer cells, to spare healthy cells, to increase specificity to target tissues, and/or to be controllable even after administration. The Company’s wholly-owned pipeline comprises cell therapies engineered with Gene Circuits to target challenging liquid and solid tumor indications. Senti’s Gene Circuits have been shown preclinically to work in both NK and T cells. Senti Bio has also preclinically demonstrated the potential breadth of Gene Circuits in other modalities and diseases outside of oncology, and continues to advance these capabilities through partnerships.</p>
<div class="lb-trans"><p>Senti Bio 是一家生物技术公司，致力于为患有不治之症的患者开发新一代细胞和基因疗法。为此，Senti Bio 利用其合成生物学平台，将基因电路工程化为具有更高精度和控制力的新药物。这些基因电路旨在精确杀死癌细胞，保护健康细胞，提高对靶组织的特异性，并且/或者在给药后仍可控制。公司的全资管线包括针对难治性液体和实体肿瘤指征的基因电路工程化细胞疗法。Senti 的基因电路在临床前研究中已显示出在 NK 细胞和 T 细胞中的有效性。Senti Bio 还在临床前研究中展示了基因电路在肿瘤学以外的其他治疗方式和疾病中的潜在广泛应用，并通过合作不断推进这些能力。</p>
</div><p><strong>Availability of Other Information About Senti Bio</strong></p>
<div class="lb-trans"><p><strong>关于 Senti Bio 的其他信息的获取</strong></p>
</div><p>For more information, please visit the Senti Bio website at https://www.sentibio.com or follow Senti Bio on X (formerly Twitter) (@SentiBio) and LinkedIn (Senti Biosciences). Investors and others should note that we communicate with our investors and the public using our company website (www.sentibio.com), including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X and LinkedIn. The information that we post on our website or on X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.</p>
<div class="lb-trans"><p>欲了解更多信息，请访问 Senti Bio 网站 https://www.sentibio.com 或在 X（前身为 Twitter）上关注 Senti Bio（@SentiBio）和 LinkedIn（Senti Biosciences）。投资者和其他人应注意，我们通过公司网站（www.sentibio.com）与投资者和公众沟通，包括但不限于公司披露、投资者演示和常见问题解答、证券交易委员会的文件、新闻稿、公开电话会议记录和网络广播记录，以及在 X 和 LinkedIn 上的信息。我们在网站或 X 或 LinkedIn 上发布的信息可能被视为重要信息。因此，我们鼓励投资者、媒体和其他感兴趣的人定期查看我们发布的信息。我们网站或社交媒体的内容不应被视为在 1933 年证券法修订案下的任何文件中引用。</p>
</div><p><strong>Investor Contact:</strong></p>
<div class="lb-trans"><p><strong>投资者联系：</strong></p>
</div><p>JTC Team, LLC</p>
<div class="lb-trans"><p>JTC Team, LLC</p>
</div><p>Jenene Thomas</p>
<div class="lb-trans"><p>Jenene Thomas</p>
</div><p>(908) 824-0775</p>
<div class="lb-trans"><p>(908) 824-0775</p>
</div><p>SNTI@jtcir.com</p>
<div class="lb-trans"><p>SNTI@jtcir.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd05EZ3hNU00zTXpJNU5qUTVJekl5TURrNE9EYz0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYwNDgxMSM3MzI5NjQ5IzIyMDk4ODc="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MmVlYWFjOGMtNjhkYS00OWQwLTg0NjYtOGEyMjI2ODJkYmVmLTEyMjE0NDAtMjAyNS0xMi0xOC1lbg==/tiny/Senti-Biosciences-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/MmVlYWFjOGMtNjhkYS00OWQwLTg0NjYtOGEyMjI2ODJkYmVmLTEyMjE0NDAtMjAyNS0xMi0xOC1lbg==/tiny/Senti-Biosciences-Inc-.png"/></p>

Senti Biosciences 宣布新的就业激励授予 | SNTI 股票新闻